Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

Schizophrenia Research
D A Revicki

Abstract

The pharmacoeconomic evaluation of atypical antipsychotics for patients with schizophrenia requires focus on both clinical and quality of life effects and impact on the cost of medical resources. The results of pharmacoeconomic studies help clinicians and health care decision makers identify treatments that provide the most benefit to patients at the most acceptable cost. The cost-effectiveness of antipsychotic drugs has been evaluated using noncontrolled, mirrorimage (i.e. retrospective/prospective) cohort study designs; clinical decision analysis models; and randomized clinical trials. The current pharmacoeconomic evidence suggests that clozapine is a cost-effective therapy for neuroleptic-refractory schizophrenia and that although olanzapine and risperidone therapy may be cost neutral, they improve outcome in patients treated for schizophrenia.

References

Jun 1, 1984·Journal of Clinical Psychopharmacology·L EreshefskyN R Burch
Nov 1, 1993·The American Journal of Psychiatry·H Y MeltzerB Snitz
Jan 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·L M Davies, M F Drummond
Jan 1, 1996·Schizophrenia Bulletin·S M EssockL Hipshman
Nov 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·M G Juarez-ReyesW A Hargreaves
Sep 1, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·G VialeB J Lawrence
Dec 24, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·M A DellvaC M Beasley
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Dec 8, 1996·PharmacoEconomics·A G AwadR J Heslegrave
Aug 2, 2001·Schizophrenia Research·R J Wyatt, I Henter

❮ Previous
Next ❯

Citations

Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
Sep 17, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·L Hosák, R Bahbouh
Nov 24, 2001·BMJ : British Medical Journal·D Lyons, D M McLoughlin
Jun 5, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Andy DugganRobert Kerwin
Jul 4, 2012·Schizophrenia Research·Beenish NafeesDouglas Turkington
Dec 1, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Anita Patel
Mar 16, 2001·Expert Opinion on Pharmacotherapy·D A Revicki
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller
May 3, 2016·Revista colombiana de psiquiatría·Hoover Quitian ReyesCarlos Gómez Restrepo
Jan 11, 2013·Clinical Schizophrenia & Related Psychoses·Michele Hill, Oliver Freudenreich
Dec 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Tian-Mei SiXin Yu
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
Dec 27, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David R StruttonChristopher M Blanchette
Nov 4, 2004·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Jan 24, 2012·PharmacoEconomics·A George Awad, Lakshmi N P Voruganti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here